<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2012</study_start_year><condition>Metastases to liver</condition><condition>Metastatisk tarmkræft der udgår fra tyk- eller endetarm</condition><condition>Metastatic colon or rectal cancer</condition><condition>Colorectal cancer stage IV</condition><disease>Colorectal Cancer Stage Iv</disease><disease>Metastatisk Tarmkræft Der Udgår Fra Tyk- Eller Endetarm</disease><disease>Metastases To Liver</disease><disease>Metastatic Colon Or Rectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2530271</full_dataset_link><location>Denmark</location><study_start_month>4</study_start_month><keyword>Xeloda</keyword><keyword>irinotecan</keyword><keyword>oxaliplatin</keyword><keyword>Avastin</keyword><repository>ECRIN MDR</repository><study_status>Ongoing</study_status></additional><is_claimable>false</is_claimable><name>Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient?</name><description>Primary objectives: Aim is to investigate whether or not the cancer marker plasma TIMP-1 is related to probability of treatment response on chemotherapy with or without irinotecan
Primary endpoints: Progression free survival (PFS)</description><dates><creation>2012-04-15</creation></dates><accession>2530271</accession><cross_references><EU Clinical Trials Register>2011-005495-42</EU Clinical Trials Register></cross_references></HashMap>